Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Brain ; 145(7): 2301-2312, 2022 07 29.
Article in English | MEDLINE | ID: mdl-35373813

ABSTRACT

Pathogenic variants in A Disintegrin And Metalloproteinase (ADAM) 22, the postsynaptic cell membrane receptor for the glycoprotein leucine-rich repeat glioma-inactivated protein 1 (LGI1), have been recently associated with recessive developmental and epileptic encephalopathy. However, so far, only two affected individuals have been described and many features of this disorder are unknown. We refine the phenotype and report 19 additional individuals harbouring compound heterozygous or homozygous inactivating ADAM22 variants, of whom 18 had clinical data available. Additionally, we provide follow-up data from two previously reported cases. All affected individuals exhibited infantile-onset, treatment-resistant epilepsy. Additional clinical features included moderate to profound global developmental delay/intellectual disability (20/20), hypotonia (12/20) and delayed motor development (19/20). Brain MRI findings included cerebral atrophy (13/20), supported by post-mortem histological examination in patient-derived brain tissue, cerebellar vermis atrophy (5/20), and callosal hypoplasia (4/20). Functional studies in transfected cell lines confirmed the deleteriousness of all identified variants and indicated at least three distinct pathological mechanisms: (i) defective cell membrane expression; (ii) impaired LGI1-binding; and/or (iii) impaired interaction with the postsynaptic density protein PSD-95. We reveal novel clinical and molecular hallmarks of ADAM22 deficiency and provide knowledge that might inform clinical management and early diagnostics.


Subject(s)
ADAM Proteins , Brain Diseases , Drug Resistant Epilepsy , Nerve Tissue Proteins , ADAM Proteins/genetics , ADAM Proteins/metabolism , Atrophy , Brain Diseases/genetics , Disks Large Homolog 4 Protein , Humans , Intracellular Signaling Peptides and Proteins , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism
2.
Am J Hum Genet ; 105(3): 493-508, 2019 09 05.
Article in English | MEDLINE | ID: mdl-31447100

ABSTRACT

Histones mediate dynamic packaging of nuclear DNA in chromatin, a process that is precisely controlled to guarantee efficient compaction of the genome and proper chromosomal segregation during cell division and to accomplish DNA replication, transcription, and repair. Due to the important structural and regulatory roles played by histones, it is not surprising that histone functional dysregulation or aberrant levels of histones can have severe consequences for multiple cellular processes and ultimately might affect development or contribute to cell transformation. Recently, germline frameshift mutations involving the C-terminal tail of HIST1H1E, which is a widely expressed member of the linker histone family and facilitates higher-order chromatin folding, have been causally linked to an as-yet poorly defined syndrome that includes intellectual disability. We report that these mutations result in stable proteins that reside in the nucleus, bind to chromatin, disrupt proper compaction of DNA, and are associated with a specific methylation pattern. Cells expressing these mutant proteins have a dramatically reduced proliferation rate and competence, hardly enter into the S phase, and undergo accelerated senescence. Remarkably, clinical assessment of a relatively large cohort of subjects sharing these mutations revealed a premature aging phenotype as a previously unrecognized feature of the disorder. Our findings identify a direct link between aberrant chromatin remodeling, cellular senescence, and accelerated aging.


Subject(s)
Cellular Senescence/physiology , Histones/physiology , Aneuploidy , Cell Nucleolus/metabolism , Child , Chromatin/metabolism , DNA Methylation , Female , Histones/chemistry , Humans , Infant , Male , Middle Aged
3.
J Neurol Neurosurg Psychiatry ; 89(6): 579-585, 2018 06.
Article in English | MEDLINE | ID: mdl-29326295

ABSTRACT

OBJECTIVE: Trials for additional or alternative treatments for cervical dystonia (CD) are scarce since the introduction of botulinum neurotoxin (BoNT). We performed the first trial to investigate whether dystonic jerks/tremor in patients with CD respond to the selective serotonin reuptake inhibitor (SSRI) escitalopram. METHODS: In a randomised, double-blind, crossover trial, patients with CD received escitalopram and placebo for 6 weeks. Treatment with BoNT was continued, and scores on rating scales regarding dystonia, psychiatric symptoms and quality of life (QoL) were compared. Primary endpoint was the proportion of patients that improved at least one point on the Clinical Global Impression Scale for jerks/tremor scored by independent physicians with experience in movement disorders. RESULTS: Fifty-threepatients were included. In the escitalopram period, 14/49 patients (29%) improved on severity of jerks/tremor versus 11/48 patients (23%) in the placebo period (P=0.77). There were no significant differences between baseline and after treatment with escitalopram or placebo on severity of dystonia or jerks/tremor. Psychiatric symptoms and QoL improved significantly in both periods compared with baseline. There were no significant differences between treatment with escitalopram and placebo for dystonia, psychiatric or QoL rating scales. During treatment with escitalopram, patients experienced slightly more adverse events, but no serious adverse events occurred. CONCLUSION: In this innovative trial, no add-on effect of escitalopram for treatment of CD with jerks was found on motor or psychiatric symptoms. However, we also did not find a reason to withhold patients treatment with SSRIs for depression and anxiety, which are common in dystonia. TRIAL REGISTRATION NUMBER: NTR2178.


Subject(s)
Citalopram/therapeutic use , Dystonic Disorders/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Torticollis/drug therapy , Tremor/drug therapy , Adult , Aged , Aged, 80 and over , Cross-Over Studies , Double-Blind Method , Dystonic Disorders/complications , Female , Humans , Male , Middle Aged , Quality of Life , Torticollis/complications , Treatment Outcome , Tremor/complications
4.
Ned Tijdschr Geneeskd ; 155: A2080, 2011.
Article in Dutch | MEDLINE | ID: mdl-21649943

ABSTRACT

A 64-year-old woman had acute central vision loss of her left eye. She also had a pulsating mass in the left side of her neck. It appeared the vision loss was caused by a thromboembolism that originated from an aneurysm of the left carotid artery.


Subject(s)
Aneurysm/complications , Blindness/etiology , Carotid Artery, Internal/pathology , Thromboembolism/complications , Aneurysm/diagnosis , Female , Humans , Middle Aged , Neck , Thromboembolism/diagnosis
5.
Mov Disord ; 21(1): 118-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16161139

ABSTRACT

We report on a 38-year-old patient with rapid-onset dystonia-parkinsonism (RDP) with a missense mutation in the Na/K-ATPase alpha3 subunit (ATP1A3). Asymmetrical parkinsonian symptoms evolved over a year. After a stable episode of another 2.5 years, overnight he developed oromandibular dystonia and more severe parkinsonian symptoms. We conclude that RDP should be considered as a rare cause of levodopa-unresponsive parkinsonism even if there is no family history and the classic presentation is lacking.


Subject(s)
Dystonic Disorders/diagnosis , Meige Syndrome/diagnosis , Parkinson Disease/diagnosis , Parkinsonian Disorders/diagnosis , Adult , Diagnosis, Differential , Dominance, Cerebral/genetics , Dysarthria/diagnosis , Dysarthria/genetics , Dystonic Disorders/genetics , Follow-Up Studies , Humans , Male , Meige Syndrome/genetics , Mutation, Missense , Neurologic Examination , Parkinson Disease/genetics , Parkinsonian Disorders/genetics , Phenotype , Recurrence , Sodium-Potassium-Exchanging ATPase/genetics
SELECTION OF CITATIONS
SEARCH DETAIL